My young son has been diagnosed with Perthes Disease. Standard medical treatments have little to offer except surgical correction
after the hips become damaged. Are there supplements that might help to prevent Perthes symptoms from developing?
Maybe. Before discussing them, let’s take an overview of the ailment.
Perthes Disease (aka ‘Legg-Calve-Perthes’) is a childhood disease with symptoms that continue into adulthood. Since it is
defined by its symptoms rather than by its causes, it may actually encompass several different diseases with similar symptoms
but entirely different causes.
The main feature of most Perthes cases is damage to the head of the femur — the leg bone that forms the ‘ball’ of the hip’s
ball-and-socket joint. In Perthes, the blood supply to the femoral head is interrupted during childhood, and the bone tissue
dies. The damaged bone is removed by the body’s scavenging mechanisms, and the femur then tries to replace it. The trouble
is, the regrown ‘ball’ is usually too small and non-spherical to perform its proper function. The adult Perthes patient therefore
ends up with a hip joint that works poorly, causes pain, and eventually fails and must be surgically replaced.
Ideally, one would like to halt the original damage to the bone before it becomes serious. In a child, the body can usually
repair such a small amount of damage, leaving no long-term disability. To achieve this, various schemes have been proposed
and tried over many decades — traction, leg braces, range-of-motion exercises, and surgical interventions. But the latest
word on the benefits of these treatments is that none of them work well, and most of them don’t work at all. Most Perthes
patients therefore suffer severe damage to the hip and require hip replacement later in life.
The causes of Perthes
It is fairly well accepted that Perthes disease is usually caused by the blockage of blood flow to the femoral head by chronic
blood clots in the blood vessels that serve it. But why these blood clots should occur in children with Perthes is not understood.
There is abundant evidence that the condition can be hereditary, and it is known that many Perthes patients have a defective
gene for a blood clotting factor (the ‘Factor V Leiden’ mutation). Other suggested explanations are: other problems with blood
clotting; inflammation in the femur due to chronic infections; defects in the growth hormone system; or traumatic injuries
to the femur.
Supplements for inhibiting blood clotting
Since the prevailing view is that most Perthes cases are the result of excessive blood clotting in the femur, we will look
first at supplements that may regulate this process. This discussion adopts a rather naïve view of the subject — we make the
assumption that consuming substances that lower the blood’s clotting tendency will reduce the number of blood clots that form.
This strategy works for some well-known conditions like deep-vein thrombosis, but it has not been tested for Perthes Disease.
While there are a number of very powerful anticoagulant drugs available, such as heparin and warfarin, these would be poor
choices for self-experimentation by Perthes patients — they are risky to use because they often thin the blood excessively
and lead to bruising and hemorrhaging.
Certain nutritional supplements offer a more promising approach because they only mildly inhibit blood clotting. These anti-clotting
supplements include:
- alpha-linolenic acid (source: hemp seed oil)
- DHA, EPA (source: fish oil)
- Cat’s Claw (plants of the genus Uncaria)
- folic acid (vitamin B9)
- idebenone (inhibits platelet aggregation)
- L-arginine (vasodilator)
- green tea extract (inhibits platelet aggregation)
Supplements for removing blood clots
The term ‘fibrinolysis’ means the breaking up of blood clots by dissolving the ‘fibrin’ that holds them together. Agents that
encourage fibrinolysis might be useful in preventing Perthes-related bone damage:
Supplements for reducing inflammation
Antioxidants offer another approach to prevention, based on the inflammation theory of Perthes. This theory holds that inflammation
causes vascular injury in the femur and results in loss of blood supply to the femoral head.
It is generally accepted that inflammation can be caused by free radicals, and it is widely believed that antioxidant supplementation
can reduce inflammation. Therefore, it seems plausible that antioxidant supplements might reduce the progression of Perthes.
Since antioxidant research is still in its infancy, one can only guess at which antioxidants might be the most effective in
suppressing Perthes development — it would make sense to use a variety of antioxidants, such as the following:
- Pine Bark Extract (OPCs, catechins)
- Vitamin C and E
- N-Acetyl-Cysteine
- Sodium Selenate (selenium)
- Quercetin
- trans-Ferulic Acid
- alpha-Lipoic Acid
- Rosmarinic Acid
- Idebenone
Supplements for preventing bone damage
Bone and joint enhancers might also be useful in preventing Perthes symptoms, since they supply raw materials for bone and
cartilage formation and for producing the ‘synovial fluid’ that cushions joints. Perthes patients are known to be deficient
in some of these substances (namely, the glycosaminoglycans). Two bone and joint enhancers are especially worth considering
as supplements:
- glucosamine sulfate (increases viscosity of synovial fluid, stimulates glycosaminoglycan and hyaluronan synthesis)
- chondroitin sulfate
A major component of the synovial fluid, hyaluronan, can be synthesized by the body from glucosamine and chondroitin, and
is not required as a separate supplement.
Why haven’t these ideas been tested?
The suggestions I’ve made here are speculative, since they have not been subjected to clinical testing in a controlled manner.
But they are obvious candidate treatments if one accepts the prevailing theories about what causes Perthes Disease. So, why
hasn’t their obviousness caused them to be tested by bone disease specialists? Most likely the reasons include: a lack of
interest in nutritional supplements by the medical industry and by government, and the outrageous costs of conducting clinical
trials — costs that have been run through the roof by government regulations.
Don’t look for much official progress in Perthes or many other medical conditions anytime soon unless it comes from China
or other technologically advanced Asian countries. Medical progress in western societies is slowing to a crawl because we
have allowed our governments to stifle innovation and medical advances under the pretense of ‘protecting the public’. Nowadays
we are more likely to find treatments for some of these medical conditions by self-experimentation than we are by waiting
for mainstream medicine to find them.
Conclusion
Perthes Disease is a degeneration of the head of the femur, thought to be caused by a disruption of the blood supply to that
part of the bone. Blood clots are thought to be involved. Standard medical treatments do not prevent or slow this disease.
On the other hand, the regular use of nutritional supplements that mildly inhibit blood clotting, or that encourage the breakup
of such clots, might inhibit the progression of Perthes. Antioxidants could also be useful, if the inflammation theory of
Perthes turns out to be valid.
— Dr. Alexis Zarkov, Ph.D.
You can contact Dr. Zarkov at AskDrZarkov@yahoo.com.
Last modified 2005.Mar.24
References
Legg-Calve-Perthes disease. Part II: Prospective multicenter study of the effect of treatment on outcome. J Bone Joint Surg Am. 2004 Oct;86-A(10):2121-34.
Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum. 1993 Aug;23(1):47-69.
Mechanism of early metabolism disorders and immunological reactivity in children with Perthes disease Lik Sprava. 2001 Jan-Feb;(1):56-61.
Alpha-linolenic acid and cardiovascular diseases. J Nutr Health Aging. 2001;5(3):179-83.
Glucosamine Sulfate (monograph)
Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging. 2003;20(14):1041-60.
Urine glycosaminoglycans in children with transient hip synovitis and Perthes disease. J Pediatr Orthop B. 2005 Mar;14(2):92-96.
Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res. 1999 Nov 1;96(3):229-37.
Evaluation of anticoagulant system in Turkish children with Perthes disease. Pediatr Int. 2005 Feb;47(1):43-8.
Idebenone (monograph)
Arginine Nutrition and Cardiovascular Function J Nutr. 2000 Nov;130(11):2626-9.
L-arginine and atherothrombosis. J Nutr. 2004 Oct;134(10 Suppl):2798S-2800S; discussion 2818S-2819S.
n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004 Jul;107(1):1-11.
An assessment of endocrine function in boys with Perthes’ disease. Clin Orthop. 1986 Aug;(209):124-8.
Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004 Oct;122(4):339-52. Epub 2004 Aug 26.
Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in
man and experimental animals. Vet Pathol. 2003 Jul;40(4):345-54.
Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res. 1994 Apr;35(4 Pt 1):383-8.
Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr. 1998 May;132(5):885-8.
Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 Dec;86-A(12):2642-7.
The role of coagulation abnormalities in the development of Perthes’ disease. J Bone Joint Surg Br. 2000 Jul;82(5):744-6.
Does thrombophilia play an aetiological role in Legg-Calve-Perthes disease? J Bone Joint Surg Br. 1999 Jul;81(4):686-90.
The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease. Pediatrics. 2001 Jun;107(6):1329-34.
Resistance to activated protein C and Legg-Perthes disease. Clin Orthop. 1997 May;(338):139-52.
The most severe forms of Perthes’ disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg Br. 2004 Apr;86(3):426-9.
Effect of rhyncophylline on platelet aggregation and experimental thrombosis Yao Xue Xue Bao. 1991;26(4):246-9
Inhibitory effect of rhynchophylline on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao. 1992 Mar;13(2):126-30.
Vitamin E improves fibrinolytic activity in patients with coronary spastic angina. Thromb Res. 2004;113(6):345-51.
Disclaimer: The information provided in this “Ask Dr. Zarkov” article contains no medical advice whatsoever — it contains
‘biological information’. Nothing in the article constitutes an effort to persuade readers to use, or not to use, this biological
information as a basis for action.